Nektar Therapeutics Investors Appeal Loss in Cancer Drug Case – Bloomberg Law


Nektar Therapeutics investors will ask the Ninth Circuit to overturn the dismissal of their would-be class case accusing the company of making false statements about a clinical trial for its flagship cancer drug.

The investors accused Nektar of misleading them about the trial for its NKTR-214 product, meant to produce cancer-fighting cells. The U.S. District Court for the Northern District of California dismissed the suit without leave to amend in December, and the investors filed a notice of appeal Jan. 29.

Judge Haywood S. Gilliam Jr. rejected investors’ falsity, scienter, and loss causation allegations Dec. 30.

The investors’ opening brief…


Please enter your comment!
Please enter your name here